Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to developing drugs and therapies focused on nasal delivery of pharmaceutical medications in neurology and infectious diseases. The company is primarily focused on innovative treatments for neurological conditions such as concussions, leveraging intranasal drug delivery technology and neurosteroids like ONP-002. With a history of scientific breakthroughs and strategic acquisitions, Oragenics aims to address critical unmet medical needs through cutting-edge drug delivery systems and therapies, including a pipeline of vaccine candidates and neuroprotective drugs.
Industries
Nr. of Employees
small (1-50)
Oragenics, Inc.
Patents
Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features
US-9963488-B2
View Details
Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features
US-9963488-B2
View DetailsProducts
Intranasal neurosteroid lead candidate (clinical-stage)
A first-in-class neurosteroid candidate delivered via an intranasal spray-dried nanoparticle formulation and single-use nasal device intended to provide rapid brain absorption for treatment of mild traumatic brain injury.
Intranasal COVID-19 vaccine candidate (NT-CoV-2 platform)
A vaccine candidate engineered for intranasal or intramuscular administration, using rapid antigen expression platforms and intranasal formulation approaches intended to elicit mucosal immunity and simplify storage/transport requirements.
Intranasal neurosteroid lead candidate (clinical-stage)
A first-in-class neurosteroid candidate delivered via an intranasal spray-dried nanoparticle formulation and single-use nasal device intended to provide rapid brain absorption for treatment of mild traumatic brain injury.
Intranasal COVID-19 vaccine candidate (NT-CoV-2 platform)
A vaccine candidate engineered for intranasal or intramuscular administration, using rapid antigen expression platforms and intranasal formulation approaches intended to elicit mucosal immunity and simplify storage/transport requirements.
Services
Design and operational coordination of early-phase clinical trials (including emergency department implementations) through partnerships with clinical research organizations.
Optimization of spray-dried intranasal nanoparticle formulations and development/validation of bioanalytical assays to support PK/PD and toxicology studies.
Collaborative development of spike-protein antigens using rapid CHO-based cell-line generation and evaluation of intranasal vaccine formulations aimed at mucosal immunity.
Design and operational coordination of early-phase clinical trials (including emergency department implementations) through partnerships with clinical research organizations.
Optimization of spray-dried intranasal nanoparticle formulations and development/validation of bioanalytical assays to support PK/PD and toxicology studies.
Collaborative development of spike-protein antigens using rapid CHO-based cell-line generation and evaluation of intranasal vaccine formulations aimed at mucosal immunity.
Expertise Areas
- Intranasal drug delivery
- Neurosteroid therapeutics for traumatic brain injury
- Clinical trial design and execution in emergency medicine settings
- Vaccine antigen design and intranasal vaccine development
Key Technologies
- Intranasal olfactory/trigeminal transport
- Spray-dried nanoparticle powder formulation
- Single-use intranasal delivery devices
- CHO cell-line antigen expression
News & Updates
Announcement of presentation at the 2025 BIO International Convention and attendance at the 42nd Annual National Neurotrauma Society Symposium, scheduled for June 10, 2025.
Announcement of a reverse stock split 1-for-30, dated May 28, 2025.
Approval to start a Phase II clinical trial for ONP-002 in Australia, announced on May 13, 2025.
Webinar scheduled to discuss concussion treatment landscape, ONP-002 clinical program, and strategic vision, on May 12, 2025.
Participation announcement at the conference, dated April 23, 2025.
Submission announcement for ethics committee approval, on April 9, 2025.
Announcement of presentation at the 2025 BIO International Convention and attendance at the 42nd Annual National Neurotrauma Society Symposium, scheduled for June 10, 2025.
Announcement of a reverse stock split 1-for-30, dated May 28, 2025.
Approval to start a Phase II clinical trial for ONP-002 in Australia, announced on May 13, 2025.
Webinar scheduled to discuss concussion treatment landscape, ONP-002 clinical program, and strategic vision, on May 12, 2025.
Participation announcement at the conference, dated April 23, 2025.
Submission announcement for ethics committee approval, on April 9, 2025.